Pomerantz Law Firm Investigates Allegations Against Skye Bioscience Investors

Pomerantz Law Firm Investigates Claims Against Skye Bioscience, Inc.

In a recent development that has raised concerns among investors, Pomerantz LLP has launched an investigation into potential securities fraud claims related to Skye Bioscience, Inc. (NASDAQ: SKYE). The law firm is encouraging affected investors to reach out, pointing to serious allegations regarding the company's business practices.

On October 6, 2025, Skye disclosed critical findings from the 26-week Phase 2a CBeyond™ study involving its drug, nimacimab, which is a peripherally-restricted CB1 inhibitor antibody. The press release revealed alarming results: the monotherapy arm did not meet the primary endpoint of weight loss when compared to a placebo. Additionally, preliminary analyses indicated that drug exposure levels were lower than anticipated, raising concerns about the adequacy of dosing in further studies.

This announcement had an immediate and dramatic impact on Skye's stock price, causing it to plummet by $2.85 per share—equivalent to a staggering drop of 60%, closing at just $1.90 per share on the same day. Such a dramatic decline has prompted investor outrage and has led to calls for accountability from the company's executives and directors.

The firm, Pomerantz LLP, recognized for its expertise in corporate and securities litigations, has been at the forefront of class action lawsuits for decades. Founded by the late Abraham L. Pomerantz, a pioneer in securities class action law, the firm has successfully recovered significant damages for class members in the past. Their commitment to fighting for investor rights remains a hallmark of its operations today.

For impacted investors, Pomerantz LLP advises contacting attorney Danielle Peyton for further discussion about the potential for joining a class action lawsuit. Such legal proceedings could serve as a way for investors to seek redress for alleged losses incurred as a result of Skye's disclosures.

As the investigation unfolds and more information comes to light, investors are likely to keep a close watch on developments to determine the appropriate next steps—especially in light of the firm’s history of securing multimillion-dollar settlements for victims of securities fraud and corporate misconduct. This latest case serves as a sobering reminder of the risks associated with investing in biotech firms and the importance of transparency in corporate communications.

In conclusion, if you have invested in Skye Bioscience and feel you may have been misled or harmed by recent events, reaching out to Pomerantz LLP could be crucial. It represents an opportunity to explore legal recourse and ensure that your rights as an investor are protected against possible corporate malfeasance. Stay informed, stay vigilant, and take action if necessary.